Satsuma Pharmaceuticals, Inc (STSA)

Etorro trading 970x250
Satsuma Pharmaceuticals, Inc (STSA) Logo

About Satsuma Pharmaceuticals, Inc

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California. Address: 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Satsuma Pharmaceuticals, Inc News and around…

Latest news about Satsuma Pharmaceuticals, Inc (STSA) common stock and company :

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 Nov, 2021 Yahoo! Finance

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second half of 2023 – SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic

Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors
09 Nov, 2021 Yahoo! Finance

Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors. Kollins is currently President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeuti

Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences
28 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via we

3 Stocks Insiders Are Buying
22 Oct, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Interesting STSA Put And Call Options For February 2022
21 Oct, 2021 FinancialContent

Investors in Satsuma Pharmaceuticals Inc (STSA) saw new options begin trading this week, for the February 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 120 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
20 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to ...

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
12 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately. Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings o

40 Biggest Movers From Yesterday
07 Oct, 2021 FinancialContent

Gainers Volcon, Inc. (NASDAQ: VLCN) shares jumped 97.5% to settle at $10.86 on Wednesday as the company priced its IPO at $5.50 ...

Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
28 Sep, 2021 FinancialContent
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
28 Sep, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webc

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
10 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
28 Jul, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock rose 11.46% to $2.43 during Wednesday's after-market session. Trading volume for ...

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
28 Jul, 2021 FinancialContent
Are Institutions Heavily Invested In Satsuma Pharmaceuticals, Inc.'s (NASDAQ:STSA) Shares?
27 Jul, 2021 Yahoo! Finance

If you want to know who really controls Satsuma Pharmaceuticals, Inc. ( NASDAQ:STSA ), then you'll have to look at the...

12 Health Care Stocks Moving In Friday's After-Market Session
09 Jul, 2021 FinancialContent

Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
24 Jun, 2021 FinancialContent

Gainers Aravive (NASDAQ:ARAV) stock moved upwards by 21.61% to $6.47 during Thursday's pre-market session. The ...

Satsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum
22 Jun, 2021 FinancialContent
21 Stocks Moving in Tuesday's Pre-Market Session
22 Jun, 2021 FinancialContent

Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 29.2% to $3.71 in pre-market trading as traders circulated an article ...

28 Stocks Moving in Friday's Pre-Market Session
18 Jun, 2021 FinancialContent

Gainers CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion ...

50 Biggest Movers From Yesterday
18 Jun, 2021 FinancialContent

Gainers Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO ...

34 Stocks Moving In Thursday's Mid-Day Session
17 Jun, 2021 FinancialContent

Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration ...

The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
17 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
17 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at the biggest pre-market stock movers for Thursday and it includes loads of medical stocks. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

25 Stocks Moving in Thursday's Pre-Market Session
17 Jun, 2021 FinancialContent

Gainers Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data ...

Satsuma Stock Is Trading Higher As STS101 Shows Favorable Pharmacokinetic Profile, Tolerability In Early-Stage Study
17 Jun, 2021 FinancialContent

Satsuma Pharmaceuticals Inc(NASDAQ: STSA)announced positive Pharmacokinetic and safety resultsfrom a Phase 1 trial ...

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
16 Jun, 2021 FinancialContent
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights
11 May, 2021 FinancialContent
Why Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)
10 May, 2021 Yahoo! Finance

Satsuma Pharmaceuticals (STSA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Satsuma Pharmaceuticals, Inc (STSA) is a NASDAQ Common Stock listed in , ,

970x250